Company intelligence / Profile preview

Trilex

Parsippany, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Trilex Pharmaceuticals was a clinical-stage biotechnology company focused on the development of novel oncology therapeutics. The company's lead candidate, TR-1 (also known as taltobulin or HTI-286), was a synthetic analog of the marine natural product hemiasterlin designed to inhibit tubulin polymerization. TR-1 was investigated in Phase 2 clinical trials for various solid tumors, including non-small cell lung cancer and ovarian cancer, demonstrating potential in overcoming taxane resistance. The company was eventually acquired by Triton Pharma, which was subsequently integrated into larger pharmaceutical entities.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Trilex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trilex.

Explore the full profile